Alzheimer's disease is a progressive neurodegenerative pathology that primarily affects memory and other cognitive functions such as language, orientation, and planning ability. It is characterized by the abnormal accumulation of proteins in the brain that disrupt communication between neurons and lead to cognitive decline.

No. Dementia is a syndrome that describes the deterioration of cognitive functions to the point of interfering with daily life. Alzheimer's is the most common cause of dementia, but it is not the only one.

No. Although the risk of developing Alzheimer's increases with age, it is not an inevitable consequence of aging. Many people age without experiencing significant cognitive decline.

Currently, there is no definitive cure for Alzheimer's. Available treatments can alleviate some symptoms, but they do not completely stop the progression of the disease, which reinforces the importance of early identification and intervention in early stages.

In its early stages, Alzheimer's can manifest as difficulty remembering recent information, problems concentrating, or difficulty planning tasks. These changes usually appear gradually and can be confused with normal aging.

Subjective cognitive decline is an individual's perception of changes in memory or other cognitive functions, even when clinical tests are still normal. It is considered an early at-risk stage, especially when there is a family history or other associated factors.

In subjective cognitive decline, changes are perceived by the individual but are not yet reflected in objective tests. In mild cognitive impairment, measurable alterations are already detected in neuropsychological evaluations, indicating that the cognitive decline process has entered a defined clinical phase.

Yes. The biological processes associated with Alzheimer's can begin years before clinical tests detect alterations. For this reason, early stages with normal test results are relevant from a preventive standpoint.

Intervening in early stages allows action to be taken when neuronal damage is still limited and potentially modifiable. This approach seeks to reduce the risk of progression and protect cognitive health before deterioration is clinically evident.

Non-modifiable factors include age and genetic predisposition. There are also modifiable lifestyle-related factors, such as a sedentary lifestyle, high blood pressure, diabetes, high cholesterol, and social isolation.

Yes. Scientific evidence indicates that maintaining healthy habits can reduce the risk of cognitive decline even in people with a genetic predisposition, which reinforces the role of preventive strategies.

Currently, there is no strategy that guarantees absolute prevention of Alzheimer's. However, it is possible to reduce the risk and delay progression by acting on modifiable factors and adopting preventive strategies based on scientific evidence.

If you start to notice persistent changes in your memory or other cognitive functions, even if they don't clearly interfere with your daily life, it is advisable to consult a healthcare professional. Early assessment allows for the identification of possible risk factors and intervention before deterioration becomes clinically evident.

For persistent memory changes, the neurologist is the professional of reference, specializing in the evaluation and monitoring of cognitive decline. A specialized assessment allows for the identification of risk factors, the exclusion of other causes, and the guidance of the most appropriate early intervention strategies.

FontUp® is a food supplement formulated with epigallocatechin-3-gallate (EGCG), a bioactive compound from green tea widely studied in the field of brain health. It is aimed at protecting cognitive health in early stages and in contexts at risk of developing Alzheimer's, within a preventive and multidimensional approach.

FontUp® was evaluated in the PENSA clinical study, conducted on individuals with subjective cognitive decline and a higher risk of developing Alzheimer's. The trial analyzed the impact of an early intervention over 12 months.

In the clinical study, the group that received FontUp® showed a 50% improvement in global cognition compared to the placebo group, and a higher percentage of participants experienced an improvement in their cognitive performance. A sustained effect over time and a reduction in the risk of dementia were also observed.

EGCG acts on multiple processes involved in brain aging, including the modulation of oxidative stress, inflammation, and synaptic plasticity. Its multifactorial mechanism makes it a compound of interest within preventive strategies aimed at protecting cognitive function.

No. FontUp® is a food supplement, not a medicine. It does not replace any medical treatment. It is part of a preventive strategy aimed at protecting cognitive health in early stages.

FontUp® is especially indicated for adults experiencing subjective memory complaints or risk factors associated with the development of Alzheimer's. Its use becomes more relevant in early stages, when changes are still mild.

No. FontUp® is intended for initial phases where there is no clinical diagnosis yet. For any persistent symptoms, it is recommended to consult a neurologist.

The recommended daily dose is five capsules divided into three doses: two in the morning, one at midday, and two at night.

FontUp® was evaluated in a 12-month clinical study. The observed benefits were associated with continuous use within a preventive approach.

Yes. It is formulated for daily and continuous use, respecting the recommended dose.

FontUp® was well tolerated in the clinical study. The recommended daily dose should not be exceeded or combined on the same day with other products containing green tea.

In case of pregnancy, lactation, or medical treatment, it is recommended to consult a healthcare professional.